Patent · US Active

Methods and compositions for treatment of a genetic condition

US10196651B2 · kind B2 · utility

13Cited by

32References

17Claims

0Family size

Assignee

Sangamo Therapeutics, Inc. · US

Inventors

Anthony J. Conway · Chatfield, US
Gregory J. Cost · Berkeley, US
Russell DeKelver · Daly City, US
Edward J. Rebar · Richmond, US
Andreas Reik · Richmond, US
Fyodor Urnov · Richmond, US
Jianbin Wang · Richmond, US
H. Steve Zhang · Richmond, US

Key dates

Filing date	Dec 19, 2017
Grant date	Feb 5, 2019
Priority date	—
Expiry date	Dec 27, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y301/21004
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a BCL11A gene for the modification of the BCL11A gene and for modification of globin expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.